VBC101-F11 / VelaVigo - LARVOL DELTA

First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies (clinicaltrials.gov) - P1/2 | N=310 | Recruiting | Sponsor: VelaVigo Bio Inc | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • Oncology • Solid Tumor

First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies (clinicaltrials.gov) - P1/2 | N=310 | Not yet recruiting | Sponsor: VelaVigo Bio Inc

New P1/2 trial • Oncology • Solid Tumor

VBC101-F11: An innovative EGFR/cMet bispecific antibody drug conjugate (ADC) targeting key oncogenic drivers in solid tumors (AACR 2024) - "This innovative design distinguishes VBC101-F11 from other EGFR/cMet-targeting agents on the market or in clinical trials (ABBV399 or AZD9592), optimizing both efficacy and safety.1. Further payload exploration, such as DNA replication inhibitor, has also yielded promising results, with VBC101-F11-new payload showing comparable efficacy to the same class ADC AZD9592 in models with low EGFR and high cMet expression (100% TGI) and in those with moderate EGFR/cMet expression (~ 60% TGI).In summary, VBC101-F11, with unique design and distinguished attributes, has demonstrated its remarkable potential in the landscape of anti-EGFR/cMet therapies. The encouraging efficacy observed in preclinical models supports the molecule's advancement into clinical development, positioning it as a best-in-class bispecific ADC for treating tumors in patients."

Late-breaking abstract • Lung Cancer • Oncology • Solid Tumor